EUVIMEDEUVIMED entdecken
Kommentar

Comparison of risankizumab with apremilast for the treatment of moderate psoriasis

British Journal of Dermatology · 2023

DOI: 10.1093/bjd/ljad349 ↗

Kurz gefasst

Kommentar in der Zeitschrift British Journal of Dermatology, 2023. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Psoriasis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalPsoriasisHumansThalidomideSeverity of Illness IndexTreatment OutcomeDouble-Blind Method

Substanzen

risankizumabapremilastAntibodies, MonoclonalThalidomide

Zitieren

APA

(2023). Comparison of risankizumab with apremilast for the treatment of moderate psoriasis. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad349

Vancouver

Comparison of risankizumab with apremilast for the treatment of moderate psoriasis. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljad349

BibTeX
@article{euvimed2023,
  title = {Comparison of risankizumab with apremilast for the treatment of moderate psoriasis},
  journal = {British Journal of Dermatology},
  year = {2023},
  doi = {10.1093/bjd/ljad349}
}
Kostenlos starten →